BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 30363270)

  • 1.
    Pitalúa-Cortés QG; García-Pérez FO; Villaseñor-Navarro Y; Lara-Medina FU; Matus-Santos JA; Soldevilla-Gallardo I; Porras-Reyes FI; Pérez-Sánchez VM; Maldonado-Martínez HA; Pérez-Báez W; Sollozo-Dupont I
    BJR Case Rep; 2017; 3(3):20160136. PubMed ID: 30363270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
    Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
    Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
    Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
    Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
    J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
    Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
    J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer.
    Alhuseinalkhudhur A; Lubberink M; Lindman H; Tolmachev V; Frejd FY; Feldwisch J; Velikyan I; Sörensen J
    EJNMMI Res; 2020 Mar; 10(1):21. PubMed ID: 32201920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
    Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
    Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
    J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
    Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
    J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
    Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
    Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
    Henry KE; Ulaner GA; Lewis JS
    PET Clin; 2017 Jul; 12(3):269-288. PubMed ID: 28576166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy.
    Farrugia MK; Wen S; Jacobson GM; Salkeni MA
    World J Nucl Med; 2018; 17(4):275-280. PubMed ID: 30505226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.
    Vag T; Steiger K; Rossmann A; Keller U; Noske A; Herhaus P; Ettl J; Niemeyer M; Wester HJ; Schwaiger M
    EJNMMI Res; 2018 Sep; 8(1):90. PubMed ID: 30191351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
    Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J
    J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.